Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : John, Mike & Tom's Wild World of Stocks -- Ignore unavailable to you. Want to Upgrade?

To: John Pitera who wrote (221)	12/21/1999 4:29:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 2850

My sense is that you cant worry too much about the revenue and R&D expenses--I thought I had scrawled down 7M revenue/12M loss for Genset, 8M revenue and 32M loss for Celera in the last quarter, so we don't jibe--but not too important, they're not in the same niche, the Celera Gorilla premium will be paid if shotgunning makes them a leader. I guess shotgunning is already proved for smaller genomes and the world awaits the human genome data, but as I've said, the real work comes after the raw sequence is generated--and plenty of companies and research centers in on that. For a marketcap of ~300M, and the consensus being that Genset is the leading pharmacogenomics company, all I can say is that it passes the sniff test for value, but more DD is required, as long as it keeps trending up, I'm okay. I think I said 2x book, but no, cash is 34M and 90M total assets. Celera has a market cap ten times my little Genset, amazing. I should go snag the numbers for Incyte, MLNM, HGSI, and the rest of the first and second tier genomics companies, but that is more work than I wanted to put into this. For now rising tide floating all these boats. Oh, I did find something interesting about Celera last nite--"GeneTag", apparently they compiled their rat database in just seven months. I tell ya, between these SNP maps, gene expression studies, new microarray technology--it is a bit much for the stock hobbiest to digest. I understand the appeal of jumping on TMF pick, they talk a good game over there about due diligence, but I understand that people are mainly just interested in being in the right stocks at the right time and forgo the 'investing' part--investors have a way of becoming traders when they've made a profit anyway.